Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bio-Thera Delivers Positive Phase III Results For Stelara Biosimilar

Hikma Holds Exclusive Rights To Commercialize The Ustekinumab Product In The US

Executive Summary

Bio-Thera has announced positive Phase III results for its ustekinumab biosimilar candidate BAT2206, demonstrating that the product is highly similar to originator Stelara in patients with moderate to severe plaque psoriasis. 

You may also be interested in...



Bio-Thera Signs Latin American Partnership Deal For Two Undisclosed Biosimilars

The Chinese firm announced a new deal with Costa Rican company SteinCares that handed over the rights to two unnamed biosimilars in the region for an undisclosed sum.

Bio-Thera Secures FDA Approval For Sandoz-Partnered Bevacizumab Biosimilar

Bio-Thera has received US Food and Drug Administration approval for its bevacizumab biosimilar, marking the second biosimilar drug researched, developed and manufactured by a Chinese pharmaceutical company to receive US approval.

All Biosimilars Interchangeable? FDA Backs Switching With Spotlight On Science

In meta-analyses of biosimilar switching studies, FDA researchers found “zero difference in the risk of death, serious adverse events, and treatment discontinuations between participants who switched between biosimilars and reference products and participants who did not switch.”

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel